Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

HMB-45 reactivity in adrenal pheochromocytomas.

Unger PD, Hoffman K, Thung SN, Pertsemlides D, Wolfe D, Kaneko M.

Arch Pathol Lab Med. 1992 Feb;116(2):151-3.

PMID:
1733408
2.

Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.

Strong VE, Kennedy T, Al-Ahmadie H, Tang L, Coleman J, Fong Y, Brennan M, Ghossein RA.

Surgery. 2008 Jun;143(6):759-68. doi: 10.1016/j.surg.2008.02.007. Epub 2008 Apr 14.

PMID:
18549892
3.

[Pheochromocytoma--pathohistologic and immunohistochemical aspects].

Tatić S, Havelka M, Paunović I, Bozić V, Diklic A, Brasanac D, Janković R, Jancić-Zguricas M.

Srp Arh Celok Lek. 2002 Jul;130 Suppl 2:7-13. Serbian.

PMID:
12584991
4.

HMB-45 staining in pigmented pheochromocytoma.

Chetty R, Clark SP.

Arch Pathol Lab Med. 1992 Nov;116(11):1102-3. No abstract available.

PMID:
1444734
6.

S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas.

Unger P, Hoffman K, Pertsemlidis D, Thung S, Wolfe D, Kaneko M.

Arch Pathol Lab Med. 1991 May;115(5):484-7.

PMID:
1673596
8.

[Clinicomorphological aspects of adrenal pheochromocytoma diagnostics].

Khmel'nitskaia NM, Il'inskaia EV, Filippova OV.

Arkh Patol. 2011 Sep-Oct;73(5):36-40. Russian.

PMID:
22288171
9.

Immunohistochemical estimations of growth activity to predict biological behavior of pheochromocytomas.

Nagura S, Katoh R, Kawaoi A, Kobayashi M, Obara T, Omata K.

Mod Pathol. 1999 Dec;12(12):1107-11.

PMID:
10619262
10.

Differential heparanase-1 expression in malignant and benign pheochromocytomas.

Quiros RM, Kim AW, Maxhimer J, Gattuso P, Xu X, Prinz RA.

J Surg Res. 2002 Nov;108(1):44-50.

PMID:
12443714
11.

Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry.

Yuan W, Wang W, Cui B, Su T, Ge Y, Jiang L, Zhou W, Ning G.

Endocr Relat Cancer. 2008 Mar;15(1):343-50. doi: 10.1677/ERC-07-0188.

12.

Increased expression of tenascin in pheochromocytomas correlates with malignancy.

Salmenkivi K, Haglund C, Arola J, Heikkilä P.

Am J Surg Pathol. 2001 Nov;25(11):1419-23.

PMID:
11684959
13.

Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas.

Shen WT, Sturgeon C, Clark OH, Duh QY, Kebebew E.

Surgery. 2004 Dec;136(6):1129-37.

PMID:
15657566
14.

Cystic adrenal neoplasms.

Erickson LA, Lloyd RV, Hartman R, Thompson G.

Cancer. 2004 Oct 1;101(7):1537-44.

15.
16.

[Recurrent pheochromocytoma].

Sun Z, Wang Y, Li Z.

Zhonghua Wai Ke Za Zhi. 1998 Jan;36(1):59-60. Chinese.

PMID:
11715546
17.

The management of benign and malignant pheochromocytoma and abdominal paraganglioma.

Edström Elder E, Hjelm Skog AL, Höög A, Hamberger B.

Eur J Surg Oncol. 2003 Apr;29(3):278-83.

PMID:
12657240
18.

Polyoma-induced neoplasms of the mouse adrenal medulla. Characterization of the tumors and establishment of cell lines.

Tischler AS, Freund R, Carroll J, Cahill AL, Perlman RL, Alroy J, Riseberg JC.

Lab Invest. 1993 May;68(5):541-9.

PMID:
8098784
20.

Nonsporadic cases and unusual morphological features in pheochromocytoma and paraganglioma.

Lamovec J, Frković-Grazio S, Bracko M.

Arch Pathol Lab Med. 1998 Jan;122(1):63-8.

PMID:
9448019

Supplemental Content

Support Center